Engineered Skin Tissue Equivalents for Product Evaluation and Therapeutic Applications.
commercial
cosmetic
pharmaceutical
product testing
skin
tribology
Journal
Biotechnology journal
ISSN: 1860-7314
Titre abrégé: Biotechnol J
Pays: Germany
ID NLM: 101265833
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
19
01
2019
revised:
20
03
2019
pubmed:
13
4
2019
medline:
18
12
2019
entrez:
13
4
2019
Statut:
ppublish
Résumé
The current status of skin tissue equivalents that have emerged as relevant tools in commercial and therapeutic product development applications is reviewed. Due to the rise of animal welfare concerns, numerous companies have designed skin model alternatives to assess the efficacy of pharmaceutical, skincare, and cosmetic products in an in vitro setting, decreasing the dependency on such methods. Skin models have also made an impact in determining the root causes of skin diseases. When designing a skin model, there are various chemical and physical considerations that need to be considered to produce a biomimetic design. This includes designing a structure that mimics the structural characteristics and mechanical strength needed for tribological property measurement and toxicological testing. Recently, various commercial products have made significant progress towards achieving a native skin alternative. Further research involve the development of a functional bilayered model that mimics the constituent properties of the native epidermis and dermis. In this article, the skin models are divided into three categories: in vitro epidermal skin equivalents, in vitro full-thickness skin equivalents, and clinical skin equivalents. A description of skin model characteristics, testing methods, applications, and potential improvements is presented.
Identifiants
pubmed: 30977574
doi: 10.1002/biot.201900022
pmc: PMC6615970
mid: NIHMS1024041
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1900022Subventions
Organisme : Connecticut Regenerative Medicine Research Fund
ID : 15-RMBUCHC-08
Organisme : National Institute of Biomedical Imaging and Bioengineering
ID : R01EB020640
Organisme : the Connecticut Regenerative Medicine Research Fund
ID : 15-RMBUCHC-08
Organisme : NIBIB NIH HHS
ID : R01 EB020640
Pays : United States
Organisme : the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health
ID : R01EB020640
Informations de copyright
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Cell Biol Toxicol. 1999 Apr;15(2):121-35
pubmed: 10408359
Int J Pharm. 2000 Aug 10;203(1-2):211-25
pubmed: 10967443
ALTEX. 1997;14(4):165-174
pubmed: 11178502
Yonsei Med J. 2000 Dec;41(6):774-9
pubmed: 11204828
Cell Biol Toxicol. 2000;16(6):391-400
pubmed: 11254165
J Control Release. 2001 Apr 28;71(3):319-27
pubmed: 11295224
ALTEX. 2001;18(2):103-6
pubmed: 11378682
Chem Rev. 2001 Jul;101(7):1869-79
pubmed: 11710233
Br J Plast Surg. 2001 Dec;54(8):659-64
pubmed: 11728107
Exp Dermatol. 2002 Jun;11(3):217-23
pubmed: 12102660
Toxicol In Vitro. 2002 Oct;16(5):557-72
pubmed: 12206823
Skin Pharmacol Appl Skin Physiol. 2002;15 Suppl 1:4-17
pubmed: 12476005
Skin Pharmacol Appl Skin Physiol. 2002;15 Suppl 1:18-30
pubmed: 12476006
Skin Pharmacol Appl Skin Physiol. 2002;15 Suppl 1:40-58
pubmed: 12476008
Pigment Cell Res. 2003 Apr;16(2):101-10
pubmed: 12622786
Br J Dermatol. 1955 Jul;67(7):239-46
pubmed: 13239971
Toxicol In Vitro. 2004 Jun;18(3):231-43
pubmed: 15046769
Biol Pharm Bull. 2004 Apr;27(4):510-4
pubmed: 15056856
Eur J Cell Biol. 2004 Dec;83(11-12):631-45
pubmed: 15679108
Skin Res Technol. 2005 May;11(2):107-9
pubmed: 15807808
Eur J Pharm Biopharm. 2005 Jul;60(2):167-78
pubmed: 15913972
Toxicol In Vitro. 2005 Oct;19(7):925-9
pubmed: 16061350
Toxicol In Vitro. 2006 Aug;20(5):547-59
pubmed: 16455230
Biomaterials. 1991 Mar;12(2):243-8
pubmed: 1652296
Mutat Res. 2006 Jul 14;606(1-2):39-51
pubmed: 16675293
J Med Chem. 2006 Jun 29;49(13):3948-54
pubmed: 16789751
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2591-607
pubmed: 17048469
J Investig Dermatol Symp Proc. 2006 Sep;11(1):93-105
pubmed: 17069016
Nature. 2007 Feb 22;445(7130):874-80
pubmed: 17314974
Int J Cosmet Sci. 2006 Dec;28(6):453-60
pubmed: 18489290
Int J Cosmet Sci. 1998 Oct;20(5):307-16
pubmed: 18505515
Int J Cosmet Sci. 1999 Feb;21(1):51-8
pubmed: 18505530
Biomaterials. 2008 Oct;29(30):4100-7
pubmed: 18639927
Am J Pathol. 2008 Sep;173(3):815-23
pubmed: 18669614
Biomed Mater. 2008 Sep;3(3):034002
pubmed: 18689924
Biomaterials. 2009 Mar;30(8):1587-95
pubmed: 19108884
Mutat Res. 2009 Mar 17;673(2):92-9
pubmed: 19167515
Nat Genet. 2009 Feb;41(2):199-204
pubmed: 19169254
Nature. 2009 Jul 2;460(7251):53-9
pubmed: 19483674
Toxicol In Vitro. 2010 Mar;24(2):669-76
pubmed: 19720135
Toxicol In Vitro. 2010 Feb;24(1):257-66
pubmed: 19733228
Tissue Eng Part C Methods. 2010 Oct;16(5):847-54
pubmed: 19883209
Lancet. 2009 Nov 21;374(9703):1745-53
pubmed: 19932355
Conf Proc IEEE Eng Med Biol Soc. 2009;2009:6526-9
pubmed: 19964173
Skin Pharmacol Physiol. 2010;23(2):105-12
pubmed: 20016252
Chem Eng Sci. 2009 Nov 16;64(22):4553-4565
pubmed: 20161384
Science. 2010 Jun 25;328(5986):1662-8
pubmed: 20576885
J Microsc. 2010 Aug 1;239(2):99-116
pubmed: 20629916
Toxicol In Vitro. 2010 Oct;24(7):2021-9
pubmed: 20688150
Toxicol In Vitro. 1994 Apr;8(2):283-91
pubmed: 20692918
Toxicol In Vitro. 1994 Aug;8(4):635-9
pubmed: 20692977
Toxicol In Vitro. 1994 Aug;8(4):889-91
pubmed: 20693039
Pigment Cell Melanoma Res. 2011 Feb;24(1):35-50
pubmed: 21029393
Drug Discov Today. 2011 Feb;16(3-4):132-9
pubmed: 21146629
Mutagenesis. 2011 Jan;26(1):177-84
pubmed: 21164200
Expert Opin Drug Deliv. 2011 Jun;8(6):705-20
pubmed: 21446890
Actas Dermosifiliogr. 2012 Jan-Feb;103(1):5-11
pubmed: 21596361
J Colloid Interface Sci. 2012 Feb 1;367(1):1-33
pubmed: 22104280
Stem Cells Transl Med. 2012 Nov;1(11):792-802
pubmed: 23197691
PLoS One. 2013;8(3):e57741
pubmed: 23469227
Skin Res Technol. 2013 Nov;19(4):474-83
pubmed: 23581539
Lab Chip. 2013 Sep 21;13(18):3555-61
pubmed: 23674126
J Invest Dermatol. 1990 Sep;95(3):325-32
pubmed: 2384690
Front Genet. 2013 Jul 11;4:131
pubmed: 23874352
Pharmaceutics. 2012 Jan 06;4(1):26-41
pubmed: 24300178
Adv Drug Deliv Rev. 2014 Apr;69-70:81-102
pubmed: 24378581
Exp Dermatol. 2014 Jun;23(6):441-3
pubmed: 24758415
J Control Release. 2014 Sep 28;190:82-93
pubmed: 24818770
J Control Release. 2015 Jul 28;210:58-66
pubmed: 25979329
Lab Chip. 2015 Jun 21;15(12):2688-99
pubmed: 25996126
Clin Pharmacokinet. 2015 Nov;54(11):1095-106
pubmed: 26063051
J Biomed Nanotechnol. 2015 Nov;11(11):2067-80
pubmed: 26554164
Toxicol Pathol. 2016 Jun;44(4):555-63
pubmed: 26940714
Trends Biotechnol. 2016 Sep;34(9):689-699
pubmed: 27167724
J Cell Commun Signal. 2016 Jun;10(2):103-20
pubmed: 27170326
Biofabrication. 2016 Sep 08;8(3):032001
pubmed: 27606434
Clin Pharmacol. 2016 Oct 19;8:163-176
pubmed: 27799831
Sci Rep. 2016 Nov 21;6:37471
pubmed: 27869150
Biofabrication. 2016 Dec 05;9(1):015006
pubmed: 27917823
Methods Mol Biol. 2017;1570:261-278
pubmed: 28238143
Exp Dermatol. 2018 May;27(5):453-459
pubmed: 28453913
Biomed Mater. 2018 Feb 20;13(3):035003
pubmed: 29125135
J Cosmet Dermatol. 2018 Feb;17(1):8-14
pubmed: 29231284
J Wound Care. 2018 Jan 2;27(1):14-18
pubmed: 29333930
Mutat Res Genet Toxicol Environ Mutagen. 2018 May - Jun;829-830:75-86
pubmed: 29704997
Br J Dermatol. 1971 Jan;84(1):37-43
pubmed: 5573184
Ann Surg. 1981 Oct;194(4):413-28
pubmed: 6792993
Br J Dermatol. 1993 Sep;129(3):227-34
pubmed: 8286218
J Invest Dermatol. 1993 Jan;100(1):40-6
pubmed: 8423393
Acta Derm Venereol. 1995 Nov;75(6):449-50
pubmed: 8651022
J Med Chem. 1998 Mar 26;41(7):1007-10
pubmed: 9544199